Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Frontiers Recent Advances in Medical Therapy for Urological Cancers

Current therapy and drug resistance in metastatic castration-resistant prostate cancer - ScienceDirect

Cancers, Free Full-Text

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer - ecancer

Cancers, Free Full-Text

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Metastatic castration resistant prostate cancer

Cancers, Free Full-Text

Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology - ScienceDirect

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial - The Lancet Oncology

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - Beyond the Abstract

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) - The Lancet Oncology